SloveniaAndrew Knudten, a leading expert in bio-pharmaceuticals with over three decades of experience, played a pivotal role in developing and commercializing Zolgensma, a gene therapy for spinal muscular atrophy (SMA). He discusses the importance of delivery systems and the future of gene therapy during his upcoming visit to Slovenia and the MSS2026 conference in Bled. Zolgensma has treated more than 5,500 patients worldwide, including a Slovenian boy named Kris. Knudten highlights the patient-centric approach behind drug development, emphasizing quality control, reliable processes, and accessibility. His career spans major pharmaceutical companies like Amgen, Novartis, and AveXis, where he focused on production strategies, quality assurance, and leadership. He notes that early challenges in delivering gene therapies led to setbacks but recent technological advancements have revitalized the field.
Bias read (Center): The article focuses on medical innovation and scientific progress related to gene therapy, which is primarily a health/science topic. While it mentions a Slovenian child receiving treatment and references a national conference, there is no explicit political commentary, framing, or bias toward any立场
